ArticleFrontiers in pediatrics2025
Comparison of organ dysfunction patterns in pediatric hemophagocytic lymphohistiocytosis and sepsis: incidence, adverse outcomes, and cluster characteristics.
Article in Frontiers in pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Precision immunomodulation for pediatric hemophagocytic lymphohistiocytosis in intensive care.Pediatric investigation · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hemophagocytic lymphohistiocytosis (HLH) and severe sepsis share similarities in their clinical manifestations, and both have high risks of developing multiple organ dysfunction syndrome (MODS). The aim of this study was to investigate the similarities and differences in organ dysfunction patterns among pediatric patients with HLH and severe sepsis. Methods: Pediatric patients diagnosed with either HLH or severe sepsis from a tertiary children's hospital over a 5-year period were included. Eleven complications representing organ dysfunction in major systems (hepatic, cardiovascular, respiratory, renal, hematologic, neurologic, and gastrointestinal) were examined. The primary outcome was adverse outcome, defined as in-hospital death or discharge following withdrawal of advanced life-sustaining treatment. The incidence and adverse outcome rates of organ dysfunction among pediatric patients with HLH and severe sepsis were compared, along with the cumulated number of complications and the correlation networks of complications, as well as laboratory characteristics. Results: This study included 231 pediatric patients with HLH and 259 with severe sepsis. Adverse outcomes occurred in 15.2% of HLH patients and 18.9% of severe sepsis patients. In HLH, the most prevalent complications were hepatic injury (46.8%) and coagulopathy (43.3%), while adverse outcome rates were highest among patients who developed ARDS (81.8%) and heart failure (77.8%). In severe sepsis, the leading complications were shock (69.9%), respiratory failure (52.1%), and coagulopathy (51.0%); adverse outcome rates were highest among patients with heart failure (67.5%), hepatic failure (61.9%), and ARDS (50%). For most complications investigated, HLH showed lower incidences compared to severe sepsis, but with similar or higher adverse outcome rates. Under the same number of complications, HLH had a higher adverse outcome rates than severe sepsis. However, patients with severe sepsis tended to develop more complications (median 3 vs. 2, Conclusions: The incidence, adverse outcome rates, and clustering patterns of organ dysfunction differed between HLH and severe sepsis. Strategies to improve prognosis should vary for each condition. In HLH, preventing the development of severe organ dysfunction is crucial, whereas in severe sepsis, the emphasis should be on preventing the clustering of multiple complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.